{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:01:26Z","timestamp":1784779286235,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82472979"],"award-info":[{"award-number":["No. 82472979"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Anhui Provincial Natural Science Foundation Youth Project","award":["2408085QH234"],"award-info":[{"award-number":["2408085QH234"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00210-026-05408-4","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:40:23Z","timestamp":1778046023000},"page":"16015-16035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polyethylene glycol\u2013liposomal doxorubicin triggers ferroptosis in breast cancer through the KEAP1\/NRF2 signaling pathway"],"prefix":"10.1007","volume":"399","author":[{"given":"Yuanyuan","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingling","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"5408_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12012-024-09952-4","volume":"25","author":"B Buchalska","year":"2025","unstructured":"Buchalska B, Kaminska K, Kowara M, Sobiborowicz-Sadowska A, Cudnoch-Jedrzejewska A (2025) Doxorubicin or Epirubicin versus Liposomal Doxorubicin therapy-differences in cardiotoxicity. Cardiovasc Toxicol 25:248\u2013268","journal-title":"Cardiovasc Toxicol"},{"key":"5408_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41419-023-05930-w","volume":"14","author":"Z Chen","year":"2023","unstructured":"Chen Z et al (2023) Ferroptosis as a potential target for cancer therapy. Cell Death Dis 14:460","journal-title":"Cell Death Dis"},{"key":"5408_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2165\/00003088-200241060-00004","volume":"41","author":"R Danesi","year":"2002","unstructured":"Danesi R, Fogli S, Gennari A, Conte P, Del Tacca M (2002) Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 41:431\u2013444","journal-title":"Clin Pharmacokinet"},{"key":"5408_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155458","volume":"126","author":"Y Deng","year":"2024","unstructured":"Deng Y et al (2024) Xanthohumol ameliorates drug-induced hepatic ferroptosis via activating Nrf2\/xCT\/GPX4 signaling pathway. Phytomedicine 126:155458","journal-title":"Phytomedicine"},{"key":"5408_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12551-016-0244-4","volume":"9","author":"P Deshmukh","year":"2017","unstructured":"Deshmukh P, Unni S, Krishnappa G, Padmanabhan B (2017) The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev 9:41\u201356","journal-title":"Biophys Rev"},{"key":"5408_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071920","volume":"15","author":"H Dorostkar","year":"2023","unstructured":"Dorostkar H et al (2023) Reduction of Doxorubicin-induced cardiotoxicity by co-administration of smart liposomal Doxorubicin and free Quercetin: In Vitro and In Vivo studies. Pharmaceutics 15:1920","journal-title":"Pharmaceutics"},{"key":"5408_CR7","doi-asserted-by":"publisher","first-page":"8857","DOI":"10.3390\/ijms26188857","volume":"26","author":"I Fercek","year":"2025","unstructured":"Fercek I et al (2025) The Role of Skin Microbiota in Facial Dermatoses and Related Factors: A Narrative Review. Int J Mol Sci 26:8857","journal-title":"Int J Mol Sci"},{"key":"5408_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419\u2013436","journal-title":"Clin Pharmacokinet"},{"key":"5408_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","volume":"29","author":"AA Gabizon","year":"2016","unstructured":"Gabizon AA, Patil Y, La-Beck NM (2016) New insights and evolving role of pegylated liposomal Doxorubicin in cancer therapy. Drug Resist Updat 29:90\u2013106","journal-title":"Drug Resist Updat"},{"key":"5408_CR10","doi-asserted-by":"publisher","first-page":"e000573","DOI":"10.1136\/bmjonc-2024-000573","volume":"4","author":"AA Gabizon","year":"2025","unstructured":"Gabizon AA, Gabizon-Peretz S, Modaresahmadi S, La-Beck NM (2025) Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective. BMJ Oncol 4:e000573","journal-title":"BMJ Oncol"},{"key":"5408_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.redox.2015.03.003","volume":"5","author":"E Habib","year":"2015","unstructured":"Habib E, Linher-Melville K, Lin HX, Singh G (2015) Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress. Redox Biol 5:33\u201342","journal-title":"Redox Biol"},{"key":"5408_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102375","volume":"105","author":"AJ Kerr","year":"2022","unstructured":"Kerr AJ et al (2022) Adjuvant and neoadjuvant breast cancer treatments: a systematic review of their effects on mortality. Cancer Treat Rev 105:102375","journal-title":"Cancer Treat Rev"},{"key":"5408_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B (2021) Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12:599\u2013620","journal-title":"Protein Cell"},{"key":"5408_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/antiox10020317","volume":"10","author":"N Lee","year":"2021","unstructured":"Lee N et al (2021) xCT-driven expression of GPX4 determines sensitivity of breast cancer cells to ferroptosis inducers. Antioxidants (Basel) 10:317","journal-title":"Antioxidants (Basel)"},{"key":"5408_CR15","first-page":"323","volume":"19","author":"Y Li","year":"2020","unstructured":"Li Y et al (2020a) Erastin\/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2\/xCT pathway. Oncol Lett 19:323\u2013333","journal-title":"Oncol Lett"},{"key":"5408_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110710","volume":"130","author":"B Li","year":"2020","unstructured":"Li B et al (2020b) Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers. Biomed Pharmacother 130:110710","journal-title":"Biomed Pharmacother"},{"key":"5408_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3816\/CLM.2007.n.001","volume":"7","author":"R Manochakian","year":"2007","unstructured":"Manochakian R, Miller KC, Chanan-Khan AA (2007) Bortezomib in combination with pegylated liposomal Doxorubicin for the treatment of multiple myeloma. Clin Lymphoma Myeloma 7:266\u2013271","journal-title":"Clin Lymphoma Myeloma"},{"key":"5408_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/mds.70103","volume":"41","author":"AM Marinescu","year":"2026","unstructured":"Marinescu AM et al (2026) Cerebrospinal fluid biomarkers of NLRP3 pathway, immune dysregulation, and neurodegeneration in Parkinson\u2019s disease: a meta-analysis. Mov Disord 41:466\u2013477","journal-title":"Mov Disord"},{"key":"5408_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV et al (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31:63\u201375","journal-title":"Cardiovasc Drugs Ther"},{"key":"5408_CR20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10549-024-07387-7","volume":"207","author":"K Mokhtarpour","year":"2024","unstructured":"Mokhtarpour K, Razi S, Rezaei N (2024) Ferroptosis as a promising targeted therapy for triple negative breast cancer. Breast Cancer Res Treat 207:497\u2013513","journal-title":"Breast Cancer Res Treat"},{"key":"5408_CR21","volume":"7","author":"R Newhouse","year":"2023","unstructured":"Newhouse R et al (2023) Pegylated liposomal Doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev 7:CD006910","journal-title":"Cochrane Database Syst Rev"},{"key":"5408_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121222","volume":"312","author":"E Ozkan","year":"2023","unstructured":"Ozkan E, Bakar-Ates F (2023) Etoposide in combination with erastin synergistically altered iron homeostasis and induced ferroptotic cell death through regulating IREB2\/FPN1 expression in estrogen receptor positive-breast cancer cells. Life Sci 312:121222","journal-title":"Life Sci"},{"key":"5408_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrclinonc.2010.122","volume":"7","author":"C Palmieri","year":"2010","unstructured":"Palmieri C et al (2010) Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol 7:561\u2013574","journal-title":"Nat Rev Clin Oncol"},{"key":"5408_CR24","volume":"16","author":"AR Palvia","year":"2024","unstructured":"Palvia AR et al (2024) Cardio-Oncology\u2019s modern approaches to prevent doxorubicin-induced cardiotoxicity: a systematic review. Cureus 16:e66215","journal-title":"Cureus"},{"key":"5408_CR25","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.2165\/0003495-200868170-00008","volume":"68","author":"GL Plosker","year":"2008","unstructured":"Plosker GL (2008) Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 68:2535\u20132551","journal-title":"Drugs"},{"key":"5408_CR26","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E et al (2010) Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323\u20133329","journal-title":"J Clin Oncol"},{"key":"5408_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.4103\/0973-1482.139267","volume":"10","author":"S Rivankar","year":"2014","unstructured":"Rivankar S (2014) An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther 10:853\u2013858","journal-title":"J Cancer Res Ther"},{"key":"5408_CR28","first-page":"500","volume":"20","author":"R Rosell","year":"2023","unstructured":"Rosell R et al (2023) Biological insights in non-small cell lung cancer. Cancer Biol Med 20:500\u2013518","journal-title":"Cancer Biol Med"},{"key":"5408_CR29","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.3390\/cancers13174421","volume":"13","author":"F Schettini","year":"2021","unstructured":"Schettini F et al (2021) Anthracyclines strike back: rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer. Cancers (Basel) 13:4421","journal-title":"Cancers (Basel)"},{"key":"5408_CR30","doi-asserted-by":"publisher","first-page":"1448037","DOI":"10.3389\/fcell.2024.1448037","volume":"12","author":"Y Shen","year":"2024","unstructured":"Shen Y et al (2024) Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer. Front Cell Dev Biol 12:1448037","journal-title":"Front Cell Dev Biol"},{"key":"5408_CR31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.freeradbiomed.2018.10.426","volume":"129","author":"D Shin","year":"2018","unstructured":"Shin D, Kim EH, Lee J, Roh JL (2018) Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer. Free Radic Biol Med 129:454\u2013462","journal-title":"Free Radic Biol Med"},{"key":"5408_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1148\/radiol.09091196","volume":"255","author":"SA Solazzo","year":"2010","unstructured":"Solazzo SA et al (2010) Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology 255:62\u201374","journal-title":"Radiology"},{"key":"5408_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1159\/000540369","volume":"47","author":"LM Tseng","year":"2024","unstructured":"Tseng LM et al (2024) Comparison of the efficacy, safety, and quality of life of pegylated liposomal doxorubicin-cyclophosphamide versus epirubicin-cyclophosphamide in patients with early-stage HER2-negative breast cancer: a prospective, randomized, multicenter, phase II study. Oncol Res Treat 47:484\u2013495","journal-title":"Oncol Res Treat"},{"issue":"1348\u20131350","key":"5408_CR34","first-page":"e1342","volume":"12","author":"KL Tuttle","year":"2024","unstructured":"Tuttle KL et al (2024) Phenotypes of hypersensitivity reactions to pegylated liposomal doxorubicin: Safety and efficacy of 128 rapid desensitizations. J Allergy Clin Immunol Pract 12(1348\u20131350):e1342","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5408_CR35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/17435889.2.3.345","volume":"2","author":"A Udhrain","year":"2007","unstructured":"Udhrain A, Skubitz KM, Northfelt DW (2007) Pegylated liposomal Doxorubicin in the treatment of AIDS-related Kaposi\u2019s sarcoma. Int J Nanomedicine 2:345\u2013352","journal-title":"Int J Nanomedicine"},{"key":"5408_CR36","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.2147\/OTT.S142154","volume":"10","author":"FJ Velloso","year":"2017","unstructured":"Velloso FJ et al (2017) The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. Onco Targets Ther 10:5491\u20135524","journal-title":"Onco Targets Ther"},{"key":"5408_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00066-023-02064-y","volume":"199","author":"K Viktorsson","year":"2023","unstructured":"Viktorsson K et al (2023) Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy. Strahlenther Onkol 199:1091\u20131109","journal-title":"Strahlenther Onkol"},{"key":"5408_CR38","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.7150\/ijbs.96748","volume":"20","author":"J Wang","year":"2024","unstructured":"Wang J et al (2024) Exploring the mechanism of ferroptosis induction by Sappanone A in cancer: insights into the mitochondrial dysfunction mediated by NRF2\/xCT\/GPX4 axis. Int J Biol Sci 20:5145\u20135161","journal-title":"Int J Biol Sci"},{"key":"5408_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2025.02.040","volume":"231","author":"Y Ye","year":"2025","unstructured":"Ye Y et al (2025) Nrf2 alleviates acute ischemic stroke induced ferroptosis via regulating xCT\/GPX4 pathway. Free Radic Biol Med 231:153\u2013162","journal-title":"Free Radic Biol Med"},{"key":"5408_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41420-023-01565-0","volume":"9","author":"X Zhao","year":"2023","unstructured":"Zhao X, Tian Z, Sun M, Dong D (2023) Nrf2: a dark horse in doxorubicin-induced cardiotoxicity. Cell Death Discov 9:261","journal-title":"Cell Death Discov"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05408-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05408-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05408-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:05:47Z","timestamp":1784775947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05408-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5408"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05408-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication, 8th Edition, 2011, USA). Moreover, all procedures were approved by the Laboratory Animal Ethics Committee of the First Affiliated Hospital of the University of Science and Technology of China (Approval No. 2021-N(A)-327).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Patient consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors give their full consent to publish the present article.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}